LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article ; Online: Impacto de una unidad de farmacia de atención primaria en la optimización del tratamiento farmacológico de pacientes diabéticos tipo 2.

Canadell-Vilarrasa, Laura / Palanques-Pastor, Tomàs / Campabadal-Prats, Cecília / Salom-Garrigues, Clara / Conde-Giner, Silvia / Bejarano-Romero, Ferran

Atencion primaria

2024 Volume 56, Issue 9, Page(s) 102945

Abstract: Objective: To evaluate the impact of a pharmaceutical intervention on treatment optimization in patients with type 2 diabetes mellitus.: Design: Before-after intervention study. SITE: Health centers of the Primary Care Department of Camp de Tarragona. ...

Title translation	Impact of a primary care pharmacy unit on the optimization of pharmacological treatment of type 2 diabetic patients.
Abstract	Objective: To evaluate the impact of a pharmaceutical intervention on treatment optimization in patients with type 2 diabetes mellitus. Design: Before-after intervention study. SITE: Health centers of the Primary Care Department of Camp de Tarragona. Participants: Patients aged ≥ 18 years, diagnosed with type 2 diabetes mellitus and under treatment with antidiabetic drugs. Interventions: Review of pharmacological treatment for type 2 diabetes mellitus and issuance of proposals for its adequacy. Main measurements: Demographic and clinical variables were collected to assess the adequacy of antidiabetic treatment. A consensus meeting was arranged with the patients' primary care physician to evaluate the proposals for improvement. The implementation of the proposals and the variation in postintervention glycemic control were assessed. Results: A total of 907 patients (59% men) were included. A total of 782 proposals for intervention were made in 65.8% of the patients reviewed. Of the proposals, 43.5% corresponded to drug discontinuation, 16% to intensification of dosing and 12.6% to exchange for a therapeutic equivalent. Of the consensual proposals, 54.7% were implemented. HbA1c was reduced by 0.2% after the intervention (7.4 vs 7.2%). Conclusions: Review of the pharmacological treatment of patients with type 2 diabetes mellitus by a pharmacist or pharmacologist facilitates its optimization.
Language	Spanish
Publishing date	2024-04-24
Publishing country	Spain
Document type	English Abstract ; Journal Article
ZDB-ID	1200787-0
ISSN	1578-1275 ; 0212-6567
ISSN (online)	1578-1275
ISSN	0212-6567
DOI	10.1016/j.aprim.2024.102945
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4054: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.

Palanques-Pastor, Tomás / López-Briz, Eduardo / Poveda Andrés, José Luis

European journal of hospital pharmacy : science and practice

2020 Volume 27, Issue 5, Page(s) 297–298

Abstract: The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the ... ...

Abstract	The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/metabolism ; Drug Delivery Systems ; Humans ; Interleukin-6/metabolism ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/metabolism
Chemical Substances	Antibodies, Monoclonal ; IL6 protein, human ; Interleukin-6 ; siltuximab (T4H8FMA7IM)
Keywords	covid19
Language	English
Publishing date	2020-06-04
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2650179-X
ISSN	2047-9964 ; 2047-9956
ISSN (online)	2047-9964
ISSN	2047-9956
DOI	10.1136/ejhpharm-2020-002322
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment.

Palanques-Pastor, Tomás / Megías-Vericat, Juan Eduardo / Bosó Ribelles, Virginia / Gómez Seguí, Inés / Poveda Andrés, José Luis

Acta haematologica

2021 Volume 145, Issue 1, Page(s) 72–77

Abstract: Acquired thrombocytopenic thrombotic purpura (aTTP) is an autoantibody-mediated disease against the enzyme A Disintegrin and Metalloprotease domain with ThromboSpondin-1 type motif 13, which until now has been treated with plasma exchange (PEX) and ... ...

Abstract	Acquired thrombocytopenic thrombotic purpura (aTTP) is an autoantibody-mediated disease against the enzyme A Disintegrin and Metalloprotease domain with ThromboSpondin-1 type motif 13, which until now has been treated with plasma exchange (PEX) and corticosteroids. A 29-year-old female patient, who presented with aTTP in the context of pregnancy, has developed multiple relapses after treatment with PEX, corticosteroids, and rituximab. Recently, caplacizumab, a nanobody against von Willebrand factor, has been approved for the treatment of aTTP. In our patient, caplacizumab achieved better disease control, with a lower platelet count restoration time, days of PEX and hospitalization duration, as compared to standard therapy, reproducing the results of clinical trials. Caplacizumab represents a significant advance in the treatment of aTTP, especially in cases of recurrent relapses.
MeSH term(s)	Adult ; Female ; Humans ; Plasma Exchange ; Pregnancy ; Pregnancy Complications, Hematologic/blood ; Pregnancy Complications, Hematologic/therapy ; Purpura, Thrombotic Thrombocytopenic/blood ; Purpura, Thrombotic Thrombocytopenic/therapy ; Single-Domain Antibodies/administration & dosage
Chemical Substances	Single-Domain Antibodies ; caplacizumab (2R27AB6766)
Language	English
Publishing date	2021-08-05
Publishing country	Switzerland
Document type	Case Reports ; Clinical Trial ; Journal Article
ZDB-ID	80008-9
ISSN	1421-9662 ; 0001-5792
ISSN (online)	1421-9662
ISSN	0001-5792
DOI	10.1159/000517813
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.145: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Analysis of chemical contamination by hazardous drugs with BD HD Check

Valero García, Silvia / Centelles-Oria, María / Palanques-Pastor, Tomás / Vila Clérigues, Nieves / López-Briz, Eduardo / Poveda Andrés, José Luis

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

2021 Volume 28, Issue 7, Page(s) 1583–1593

Abstract: The presence of contamination in the healthcare work environment by one of the types of hazardous drugs, cytostatics, has been found in multiple international studies. Recent studies and guidelines recommend surface monitoring for risk assessment of ... ...

Abstract	The presence of contamination in the healthcare work environment by one of the types of hazardous drugs, cytostatics, has been found in multiple international studies. Recent studies and guidelines recommend surface monitoring for risk assessment of healthcare professionals' exposure. The availability of detection techniques is critical to successfully carry out this type of monitoring. The use of new semi-quantitative techniques allows quicker results. The main objective of this study was to determine the existence of hazardous drugs on the working surfaces in different locations of a tertiary hospital using the BD HD Check
MeSH term(s)	Antineoplastic Agents/adverse effects ; Antineoplastic Agents/analysis ; Cyclophosphamide/analysis ; Doxorubicin ; Environmental Monitoring/methods ; Equipment Contamination ; Humans ; Methotrexate/adverse effects ; Methotrexate/analysis ; Occupational Exposure/analysis ; Tertiary Care Centers
Chemical Substances	Antineoplastic Agents ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2021-09-25
Publishing country	England
Document type	Journal Article
ZDB-ID	1330764-2
ISSN	1477-092X ; 1078-1552
ISSN (online)	1477-092X
ISSN	1078-1552
DOI	10.1177/10781552211038518
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4488: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Involvement of interleukin 6 in SARS-CoV-2 infection

Palanques-Pastor, Tomás / López-Briz, Eduardo / Poveda Andrés, José Luis

European Journal of Hospital Pharmacy

siltuximab as a therapeutic option against COVID-19

2020 Volume 27, Issue 5, Page(s) 297–298

Keywords	General Pharmacology, Toxicology and Pharmaceutics ; covid19
Language	English
Publisher	BMJ
Publishing country	uk
Document type	Article ; Online
ZDB-ID	2650179-X
ISSN	2047-9964 ; 2047-9956
ISSN (online)	2047-9964
ISSN	2047-9956
DOI	10.1136/ejhpharm-2020-002322
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, Tomás / López-Briz, Eduardo / Poveda Andrés, José Luis

Abstract	The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #32499314
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book ; Online: Involvement of interleukin 6 in SARS-CoV-2 infection

Palanques-Pastor, Tomás / López-Briz, Eduardo / Poveda Andrés, José Luis

siltuximab as a therapeutic option against COVID-19

2020

Abstract	The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.
Keywords	Short report ; covid19
Language	English
Publishing date	2020-09-01 00:00:00.0
Publisher	BMJ Publishing Group Ltd
Publishing country	us
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Metyrapone as treatment in the neonatal McCune-Albright syndrome.

de Mingo, Carmen / Brugada, María / León, Sara / Moreno, Francisca / Vila, Nieves / Palanques-Pastor, Tomás / Poveda, José Luis / Orti, Carlos / García-Robles, Ana

Journal of pediatric endocrinology & metabolism : JPEM

2020

Abstract: Objectives To present a case report of succesfully metyrapone treatment of a neonatal patient with McCune-Albrigth syndrome (MAS), a rare disease caused by a genetically mosaic disorder and is characterized by variable hyperfunctional endocrinopathies, ... ...

Abstract	Objectives To present a case report of succesfully metyrapone treatment of a neonatal patient with McCune-Albrigth syndrome (MAS), a rare disease caused by a genetically mosaic disorder and is characterized by variable hyperfunctional endocrinopathies, bone dysplasia, and café-au-lait spots. Case presentation A preterm newborn was admitted to hospital and she presented difficulty controlling hypertension, café-au-lait spots, and failure to thrive. An abdominal ultrasound and a magnetic resonance showed a high volume of both suprarenal glands. Therefore, MAS was suspected. Laboratory data confirmed adrenocorticotropic hormone-independent Cushing's syndrome with hepatic dysfunction and metyrapone treatment was initiated. A progressive normalization of cortisol levels was achieved despite poor oral tolerance. Conclusion Our case shows that metyrapone is useful in the management of neonatal Cushing's syndrome due to McCune-Albright syndrome.
Language	English
Publishing date	2020-07-22
Publishing country	Germany
Document type	Case Reports
ZDB-ID	1231070-0
ISSN	2191-0251 ; 0334-018X
ISSN (online)	2191-0251
ISSN	0334-018X
DOI	10.1515/jpem-2020-0036
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2258: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez, Rubén / Méndez, Raúl / Palanques-Pastor, Tomás / Ballesta-López, Octavio / Borrás Almenar, Conxa / Megías Vericat, Juan Eduardo / López-Briz, Eduardo / Font-Noguera, Isabel / Menéndez Villanueva, Rosario / Román Iborra, José Andrés / Poveda Andrés, José Luis

European journal of hospital pharmacy : science and practice

2021 Volume 29, Issue e1, Page(s) e41–e45

Abstract: Objectives: To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis.: Methods: This was an ... ...

Abstract	Objectives: To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis. Methods: This was an observational retrospective study of hospitalised patients treated with baricitinib for severe COVID-19. Outcomes were clinical improvement on an ordinal scale of 1-8 on day 1 of baricitinib compared with day 14 (where 8=death and 1=not hospitalised with no limitations of activities), overall survival, time to recovery since baricitinib treatment started (days until hospital discharge) and laboratory parameters related to COVID-19 poor prognosis. Adverse events related to baricitinib during the admission period were also reported. Results: Forty-three patients (70% men, mean age 70 years (IQR 54-79)) treated with baricitinib daily for 6 days (IQR 5-7) were included. Thirty-six patients were treated with corticosteroids (84%). Clinical improvement was 3 points (IQR 1-4) in patients on an ordinal scale of 4-6, overall survival was 100% at day 30 and day 60 with a mean time to recovery of 12 days (IQR 9-25) from start of baricitinib treatment. No adverse events of interest were found and all poor prognosis risk factors improved at day 14: interleukin-6, C-reactive protein, ferritin, lymphocytes, platelets and D-dimers. Conclusions: Patients treated with baricitinib for severe COVID-19 showed improvements in clinical and analytical values without relevant adverse events and 100% overall survival. Clinical randomised trials are needed to confirm the clinical benefit of baricitinib.
MeSH term(s)	Aged ; Azetidines ; COVID-19/drug therapy ; Female ; Humans ; Male ; Purines ; Pyrazoles ; Retrospective Studies ; SARS-CoV-2 ; Sulfonamides
Chemical Substances	Azetidines ; Purines ; Pyrazoles ; Sulfonamides ; baricitinib (ISP4442I3Y)
Language	English
Publishing date	2021-07-28
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	2650179-X
ISSN	2047-9964 ; 2047-9956
ISSN (online)	2047-9964
ISSN	2047-9956
DOI	10.1136/ejhpharm-2021-002741
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.

Palanques-Pastor, Tomás / Megías-Vericat, Juan Eduardo / Martínez, Pilar / López Lorenzo, José Luis / Cornago Navascués, Javier / Rodriguez Macias, Gabriela / Cano, Isabel / Arnan Sangerman, Montserrat / Vidriales Vicente, María Belén / Algarra Algarra, Jesús Lorenzo / Foncillas, María Ángeles / Herrera, Pilar / Botella Prieto, Carmen / Vives, Susana / Figuera Álvarez, Ángela / Cuevas Palomares, Laida / Sobas, Marta / Contento Gonzalo, Alejandro / Cuello García, Rebeca /

Amutio Diez, María Elena / De Miguel Llorente, Dunia / Navas Elorza, Begoña / Bergua Burgues, Juan Miguel / Bernal Del Castillo, Teresa / Mateos Rodríguez, María Carmen / de Cabo López, Erik / Franco Villegas, Ana Carolina / García Boyero, Raimundo / Escolano Escobar, Cristian / Seri Merino, Cristina / Cervero, Carlos / Roldán Pérez, Alicia / Hermosín Ramos, Lourdes / Cervera Calvo, Marta / Olave, María Telesa / Villafuerte Gutiérrez, Paola / de Laiglesiai, Almudena / Serrano, Josefina / Najera Irazu, María Josefa / Piñana, José Luis / Sanz, Miguel Ángel / Martínez-López, Joaquín / Montesinos, Pau

Leukemia & lymphoma

2021 Volume 62, Issue 12, Page(s) 2928–2938

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to ... ...

Abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
MeSH term(s)	Adult ; COVID-19 ; Humans ; Leukemia, Myeloid, Acute/epidemiology ; Leukemia, Myeloid, Acute/therapy ; Lopinavir ; Risk Factors ; SARS-CoV-2
Chemical Substances	Lopinavir (2494G1JF75)
Language	English
Publishing date	2021-07-22
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2021.1948031
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito